Skip to main content
Erschienen in: Journal of General Internal Medicine 4/2014

01.04.2014 | Original Research

Cost-Effectiveness of Procalcitonin-Guided Antibiotic Therapy for Outpatient Management of Acute Respiratory Tract Infections in Adults

verfasst von: Constantinos I. Michaelidis, BA, Richard K. Zimmerman, MD, MPH, Mary Patricia Nowalk, PhD, Michael J. Fine, MD, MSc, Kenneth J. Smith, MD, MS

Erschienen in: Journal of General Internal Medicine | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

ABSTRACT

BACKGROUND

Two clinical trials suggest that procalcitonin-guided antibiotic therapy can safely reduce antibiotic prescribing in outpatient management of acute respiratory tract infections (ARTIs) in adults. Yet, it remains unclear whether procalcitonin testing is cost-effective in this setting.

OBJECTIVE

To evaluate the cost-effectiveness of procalcitonin-guided antibiotic therapy in outpatient management of ARTIs in adults.

DESIGN

Cost-effectiveness model based on results from two published European clinical trials, with all parameters varied widely in sensitivity analyses.

PATIENTS

Two hypothetical cohorts were modeled in separate trial-based analyses: adults with ARTIs judged by their physicians to require antibiotics and all adults with ARTIs.

INTERVENTIONS

Procalcitonin-guided antibiotic therapy protocols versus usual care.

MAIN MEASURES

Costs and cost per antibiotic prescription safely avoided.

KEY RESULTS

We estimated the health care system willingness-to-pay threshold as $43 (range $0–$333) per antibiotic safely avoided, reflecting the estimated cost of antibiotic resistance per outpatient antibiotic prescribed. In the cohort including all adult ARTIs judged to require antibiotics by their physicians, procalcitonin cost $31 per antibiotic prescription safely avoided and the likelihood of procalcitonin use being favored compared to usual care was 58.4 % in a probabilistic sensitivity analysis. In the analysis that included all adult ARTIs, procalcitonin cost $149 per antibiotic prescription safely avoided and the likelihood of procalcitonin use being favored was 2.8 %.

CONCLUSIONS

Procalcitonin-guided antibiotic therapy for outpatient management of ARTIs in adults would be cost-effective when the costs of antibiotic resistance are considered and procalcitonin testing is limited to adults with ARTIs judged by their physicians to require antibiotics.
Literatur
1.
Zurück zum Zitat Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA. 2009;302(7):758–66.PubMedCrossRef Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA. 2009;302(7):758–66.PubMedCrossRef
2.
Zurück zum Zitat Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA. 1997;278(11):901–4.PubMedCrossRef Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA. 1997;278(11):901–4.PubMedCrossRef
3.
Zurück zum Zitat Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis. 2001;33(5):757–62.PubMedCrossRef Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis. 2001;33(5):757–62.PubMedCrossRef
4.
Zurück zum Zitat Huchon GJ, Gialdroni-Grassi G, Leophonte P, Manresa F, Shaberg T, Woodhead M. Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey. Eur Respir J. 1996;9(8):1590–5.PubMedCrossRef Huchon GJ, Gialdroni-Grassi G, Leophonte P, Manresa F, Shaberg T, Woodhead M. Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey. Eur Respir J. 1996;9(8):1590–5.PubMedCrossRef
5.
Zurück zum Zitat Steinman MA, Landefield CS, Gonzales R. Predictors of broad-spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. JAMA. 2003;289(6):719–25.PubMedCrossRef Steinman MA, Landefield CS, Gonzales R. Predictors of broad-spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. JAMA. 2003;289(6):719–25.PubMedCrossRef
6.
Zurück zum Zitat Arroll B, Kenealy T. Antibiotics for the common cold and acute purulent rhinitis (review). Cochrane Database Syst Rev. 2010:CD000247. Arroll B, Kenealy T. Antibiotics for the common cold and acute purulent rhinitis (review). Cochrane Database Syst Rev. 2010:CD000247.
7.
Zurück zum Zitat Smith SM, Fahey T, Smucny J, Becker LA. Antibiotics for acute bronchitis (review). Cochrane Database Syst Rev. 2012:CD000245. Smith SM, Fahey T, Smucny J, Becker LA. Antibiotics for acute bronchitis (review). Cochrane Database Syst Rev. 2012:CD000245.
8.
Zurück zum Zitat Ahovuo-Saloranta A, Rautakorpi UM, Borisenko OV, Liira H, Williams JW, Mäkelä M. Antibiotics for acute maxillary sinusitis (review). Cochrane Database Syst Rev. 2011:CD000243. Ahovuo-Saloranta A, Rautakorpi UM, Borisenko OV, Liira H, Williams JW, Mäkelä M. Antibiotics for acute maxillary sinusitis (review). Cochrane Database Syst Rev. 2011:CD000243.
9.
Zurück zum Zitat Goosens H, Ferech M, Stichele RB, Elseviers S. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365(9459):579–87.CrossRef Goosens H, Ferech M, Stichele RB, Elseviers S. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365(9459):579–87.CrossRef
10.
12.
Zurück zum Zitat Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev. 2009:CD003539. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev. 2009:CD003539.
13.
Zurück zum Zitat Goosens H, Guillemot D, Ferech M, et al. National campaigns to improve antibiotic use. Eur J Clin Pharmacol. 2006;62(5):373–9.CrossRef Goosens H, Guillemot D, Ferech M, et al. National campaigns to improve antibiotic use. Eur J Clin Pharmacol. 2006;62(5):373–9.CrossRef
14.
Zurück zum Zitat van der Meer V, Neven AK, van den Broek PJ, Assendelft WJJ Diagnostic value of C reactive protein in infections of the lower respiratory tract: a systematic review. BMJ. 2005;331(757):26. van der Meer V, Neven AK, van den Broek PJ, Assendelft WJJ Diagnostic value of C reactive protein in infections of the lower respiratory tract: a systematic review. BMJ. 2005;331(757):26.
15.
Zurück zum Zitat Gonzales R, Aagaard EM, Camargo CA, et al. C-reactive protein testing does not decrease antibiotic use for acute cough illness when compared to a clinical algorithm. J Emerg Med. 2011;41(1):1–7.PubMedCrossRef Gonzales R, Aagaard EM, Camargo CA, et al. C-reactive protein testing does not decrease antibiotic use for acute cough illness when compared to a clinical algorithm. J Emerg Med. 2011;41(1):1–7.PubMedCrossRef
16.
Zurück zum Zitat Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med. 2011;171(15); 1322–31.PubMedCrossRef Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med. 2011;171(15); 1322–31.PubMedCrossRef
17.
Zurück zum Zitat Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med. 2008;168(18): 2000–7.PubMedCrossRef Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med. 2008;168(18): 2000–7.PubMedCrossRef
18.
Zurück zum Zitat Burkhardt O, Ewig S, Haagen U, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J. 2010;36(3): 601–7.PubMedCrossRef Burkhardt O, Ewig S, Haagen U, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J. 2010;36(3): 601–7.PubMedCrossRef
19.
Zurück zum Zitat Mainous AG, Hueston WJ. The cost of antibiotics in treating upper respiratory tract infections in a Medicaid population. Arch Fam Med. 1998;7(Jan/Feb):45–9.PubMedCrossRef Mainous AG, Hueston WJ. The cost of antibiotics in treating upper respiratory tract infections in a Medicaid population. Arch Fam Med. 1998;7(Jan/Feb):45–9.PubMedCrossRef
21.
Zurück zum Zitat Gonzales R, Corbett KK, Wong S, et al. “Get Smart Colorado,” Impact of a mass media campaign to improve community antibiotic use. Med Care. 2008;46(6):597–605.PubMedCrossRef Gonzales R, Corbett KK, Wong S, et al. “Get Smart Colorado,” Impact of a mass media campaign to improve community antibiotic use. Med Care. 2008;46(6):597–605.PubMedCrossRef
22.
Zurück zum Zitat Oppong R, Billingsley K, Nuttall J, Hood K, Smith RD, Cost J. The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries. Eur J Health Econ. 2013;14(2):197–209.PubMedCrossRef Oppong R, Billingsley K, Nuttall J, Hood K, Smith RD, Cost J. The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries. Eur J Health Econ. 2013;14(2):197–209.PubMedCrossRef
23.
Zurück zum Zitat Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analysis: using national measures to create condition-specific values. Med Care. 1998;36(6):778–92.PubMedCrossRef Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analysis: using national measures to create condition-specific values. Med Care. 1998;36(6):778–92.PubMedCrossRef
24.
Zurück zum Zitat Smith KJ, Wateska A, Nowalk MP, Raymund M, Lee BY, Zimmerman RK, Fine MJ. Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia. J Gen Intern Med. 2013;28(9):1157–64.PubMedCrossRef Smith KJ, Wateska A, Nowalk MP, Raymund M, Lee BY, Zimmerman RK, Fine MJ. Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia. J Gen Intern Med. 2013;28(9):1157–64.PubMedCrossRef
25.
Zurück zum Zitat Bush K, Courvalin P, Dantas G, et al. Tackling antibiotic resistance. Nat Rev Microbiol. 2011; December(9):894–6. Bush K, Courvalin P, Dantas G, et al. Tackling antibiotic resistance. Nat Rev Microbiol. 2011; December(9):894–6.
26.
27.
Zurück zum Zitat Albrich WC, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”: an international, multicenter poststudy survey (ProREAL). Arch Intern Med. 2012;172(9):715–22.PubMedCrossRef Albrich WC, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”: an international, multicenter poststudy survey (ProREAL). Arch Intern Med. 2012;172(9):715–22.PubMedCrossRef
30.
Zurück zum Zitat Wise R, Hart T, Cars O, et al. Antimicrobial resistance is a major threat to public health. BMJ. 1998;September 5(317):609–10. Wise R, Hart T, Cars O, et al. Antimicrobial resistance is a major threat to public health. BMJ. 1998;September 5(317):609–10.
31.
Zurück zum Zitat Hersh AL, Shapiro DJ, Pavia AT, Shah S. Antibiotic prescribing in ambulatory pediatrics in the United States. Pediatrics. 2011;128(6):1053–61.PubMedCrossRef Hersh AL, Shapiro DJ, Pavia AT, Shah S. Antibiotic prescribing in ambulatory pediatrics in the United States. Pediatrics. 2011;128(6):1053–61.PubMedCrossRef
32.
Zurück zum Zitat Hersh AL, Shapiro DJ, Hicks LA. Antibiotic prescribing in ambulatory care in the United States: estimates from the National Ambulatory and National Hospital Ambulatory Medical Care Surveys (NAMCS/HAMCS). Abstract, 2012 IDWeek Conference. Hersh AL, Shapiro DJ, Hicks LA. Antibiotic prescribing in ambulatory care in the United States: estimates from the National Ambulatory and National Hospital Ambulatory Medical Care Surveys (NAMCS/HAMCS). Abstract, 2012 IDWeek Conference.
Metadaten
Titel
Cost-Effectiveness of Procalcitonin-Guided Antibiotic Therapy for Outpatient Management of Acute Respiratory Tract Infections in Adults
verfasst von
Constantinos I. Michaelidis, BA
Richard K. Zimmerman, MD, MPH
Mary Patricia Nowalk, PhD
Michael J. Fine, MD, MSc
Kenneth J. Smith, MD, MS
Publikationsdatum
01.04.2014
Verlag
Springer US
Erschienen in
Journal of General Internal Medicine / Ausgabe 4/2014
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-013-2679-7

Weitere Artikel der Ausgabe 4/2014

Journal of General Internal Medicine 4/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.